Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

Anthropic’s Cowork brings Claude Code–style AI agents to the desktop, letting Claude access and manage local files and browse ...

Welcome to the era of "Action Drift," where your agents are negotiating trades your CRO won’t understand for another six ...

Nvidia is turning its AI firepower toward the hardest problems in medicine, striking multibillion-dollar alliances with ...

Explore the impact of drug discovery automation in 2026, addressing complexity and improving decision-making across ...

Gordon died in a hotel room with a copy of his favorite children’s book, Goodnight Moon, at his side. Inside, he left ...

Information pervades the universe, yet means nothing. Meaning emerged when matter organized into systems that could ...

Deep dive into RBAC vs ReBAC for enterprise sso. Learn which authorization model fits your ciam strategy and how to avoid role explosion in complex apps.

The site, which will cost about €10.0 billion ($11.7 billion) to complete, will be the third-largest of the company’s Verbund ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Despite holding a governing trifecta, Republicans labored to steer the tightly divided House, with fewer votes and fewer ...